MYTHALLOG, AN APP FOR BLUEBIRD BIO’S OBSERVATIONAL STUDY ABOUT TRANSFUSION-DEPENDENT BETA-THALASSEMIA (TDT)
Vitaccess is proud to work with bluebird bio on their international observational study of Transfusion-Dependent beta-Thalassemia (TDT).
Transfusion-dependent beta-thalassemia is a rare blood disease that causes severe anemia requiring frequent blood transfusions. Clinical stage company bluebird bio is running an e-diary project over 3 months in 5 countries to measure the impact of the disease on patients’ daily lives.
People in the US, UK, France, Germany and Italy can download the MyThalLog app on their smartphones and record the impact of the disease on their daily lives, including the number of blood transfusions and their frequency. This is an opportunity to participate in research and help the community better understand what it’s like to live with transfusion-dependent beta-thalassemia.
The project uses a customized e-diary app called myThalLog, developed using Vitaccess’ MyRealWorld™ BYOD (“bring your own device”) digital platform, to evaluate the impact of disease for people with transfusion-dependent beta-thalassemia. The purpose of this project is to collect real-world evidence (RWE) from people living with the condition, which will help better understand the significant daily impact on patients of this condition. It will give patients a voice and increase the evidence base about living with transfusion dependent beta-thalassemia.
To participate in the study, transfusion-dependent beta-thalassemia patients simply download the MyThalLog app onto their smartphone from Android or iOS app stores. myThalLog contains an eDiary that they can then complete at their own convenience. Encrypted data are sent to a cloud-based research portal where they are aggregated and anonymised for analysis in close to real-time.
PLEASE NOTE: This app is not meant for adverse events (AEs) reporting. Please report such events to your physician.
Please watch this video to see how to download the app
bluebird bio is a clinical-stage company committed to developing gene therapies for severe genetic diseases and T cell-based immunotherapies. Headquartered in Cambridge, Massachusetts, bluebird bio has operations in the U.S. and Europe.
Stay up to date with the app by following us on Facebook and Twitter @myThalLog. For more information about the study and the MyThalLog app, please visit our FAQs page: www.vitaccess.com/mythallog/FAQs or contact us at email@example.com.